5 completed, 1 enrolling by invitation, 1 recruiting. 3 Phase 1, 3 Phase 3, 1 Phase 2.
By phase and status
Follow dapirolizumab pegol: new trials by email Literature Review of dapirolizumab pegol trials Research Report on dapirolizumab pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
DZP, Placebo - Systemic Lupus Erythematosus | Phase 3 | Recruiting | 450 | 2024-11-21 | 2026-11-02 |
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Dapirolizumab pegol - Systemic Lupus Erythematosus | Phase 3 | Enrolling by invitation | 760 | 2021-07-27 | 2026-10-15 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants
BIIB133 (Dapirolizumab pegol), Placebo - Healthy Volunteers | Phase 1 | Completed | 33 | 2020-10-14 | 2023-04-18 |
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
DZP, Placebo - Systemic Lupus Erythematosus | Phase 3 | Completed | 321 | 2020-08-12 | 2025-05-04 |
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Placebo, Dapirolizumab pegol (DZP) - Systemic Lupus Erythematosus (SLE) | Phase 2 | Completed | 182 | 2016-06-02 | 2021-06-30 |
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
CDP7657, Placebo - Immune System Diseases, Autoimmune Diseases | Phase 1 | Completed | 24 | 2013-01-01 | 2015-07-16 |
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
CDP7657, Placebo - Immune System Diseases, Autoimmune Diseases | Phase 1 | Completed | 44 | 2010-03-01 | 2013-01-04 |
Conditions studied
Lupus Erythematosus, Systemic (6) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Immune System Diseases (2) · Skin and Connective Tissue Diseases (2)
Sponsors
UCB Biopharma SRL (3) · UCB Pharma (2) · Biogen (1) · UCB Biopharma S.P.R.L. (1)
Countries
Germany (6) · Belgium (5) · Bulgaria (5) · Poland (5) · Spain (5) · United States (5) · Chile (4) · Mexico (4) · Peru (4) · Romania (4) · Argentina (3) · Canada (3) · Colombia (3) · Greece (3) · Hungary (3)
Top investigators
Amina Haggag, M.D (1)
Results publications
PMID 25784719, PMID 28780512, PMID 34897375, PMID 36453450, PMID 42214397
NIH funding
2019 (3), 2023 (2), 2009 (1), 2015 (1)